Abstract: Method and systems are provided for generating compromised system scores based on encryption codes. Support-system authentication request data associated with a first client is received. A set of keys may be extracted with each key characterizing a system fault or a root cause determination of a set of a system faults. Each key may be allocated to a class based on fault severity. A compromised system score may be identified based at least in part on the fault severity of each code. The compromised system score indicating one or more processes of the client that are disabled or that have modified functionality. A result based on the compromised system score or system fault identifier may be output.
Abstract: The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
Type:
Application
Filed:
April 6, 2016
Publication date:
October 13, 2016
Applicants:
F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL)
Abstract: The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
Type:
Application
Filed:
October 18, 2012
Publication date:
April 25, 2013
Applicants:
F. HOFFMANN-LA ROCHE LTD, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), SAVIRA PHARMACEUTICALS GMBH
Inventors:
F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORAT
Abstract: The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
Type:
Application
Filed:
October 18, 2012
Publication date:
April 25, 2013
Applicants:
F. HOFFMANN-LA ROCHE LTD, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), SAVIRA PHARMACEUTICALS GMBH
Inventors:
F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORAT
Abstract: The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination comprising vinflunine and trastuzumab.
Type:
Application
Filed:
May 5, 2008
Publication date:
August 5, 2010
Applicants:
Pierre Fabre Medicament, F.HOFFMANN-LA ROCHE LTD